Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Iopofosine i-131 by Cellectar Biosciences for Secondary CNS Lymphoma: Likelihood of Approval
Iopofosine i-131 is under clinical development by Cellectar Biosciences and currently in Phase II for Secondary CNS Lymphoma. According to...
Iopofosine i-131 by Cellectar Biosciences for Primary CNS Lymphoma: Likelihood of Approval
Iopofosine i-131 is under clinical development by Cellectar Biosciences and currently in Phase II for Primary CNS Lymphoma. According to...
Iopofosine i-131 by Cellectar Biosciences for Recurrent Head And Neck Squamous Cell Carcinoma: Likelihood of Approval
Iopofosine i-131 is under clinical development by Cellectar Biosciences and currently in Phase I for Recurrent Head And Neck Squamous...
Risk adjusted net present value: What is the current valuation of Cellectar Biosciences's Iopofosine i-131?
Iopofosine i-131 is a small molecule commercialized by Cellectar Biosciences, with a leading Phase II program in Refractory Multiple Myeloma....